Skip to main content

Advertisement

Seroprevalence of hepatitis B and C in Nepal: a systematic review (1973–2017)

Article metrics

Abstract

Introduction

Hepatitis B and C represent an important co-infection for people living with HIV worldwide. Nepal wants to be part of the international mobilization for viral hepatitis elimination, and has pursued better understanding of the epidemic in its territory through scientific research.

Methods

We performed a systematic review of seroprevalence studies hepatitis B and C in Nepal following the PRISMA 2009 Flow Diagram.

Results

Fifty-four scientific publications and reports were selected for this review. Nearly a quarter of these documents have been issued in recent years and many are authored by non-governmental organizations in Nepal. The collective of information displays a wide range of alarming prevalence rates, particularly for girls and women survivors of human trafficking and a progressive participation of civil society in viral hepatitis epidemiology research in the country.

Conclusion

This paper presents a most complete review of hepatitis B and C and HIV co-infection prevalence studies in different population groups from 1973 to 2016. A comprehensive analysis of the epidemiology and apparent trends in public health research and policy making in Nepal are also addressed in this document. We expect this to be a most important tool for improvements in future interventions for both epidemics in the country.

Background

Viral hepatitis has become a leading cause of death and disability worldwide - estimated to be responsible for over 1.4 million deaths every year. Chronic viral hepatitis, mostly represented by the hepatitis B and C viruses infections (HBV and HCV, respectively), is a major cause of increasing events of high morbidity and mortality such as cirrhosis, end-stage liver disease and hepatocellular carcinoma. Both viruses are more easily transmissible than HIV [1].

The Sustainable Development Goals (SDG) establishes the year of 2030 as a desirable deadline for the end of many epidemics, including viral hepatitis. Nepal, a landlocked central Himalayan country in South Asia, has committed to the seventeen ambitious goals of SDG, and pursues to graduate from the least developed country rank by 2022. Nepal already presented remarkable achievements in infectious diseases, particularly the HIV response [2,3,4]. However, the understanding of viral hepatitis impacts to the country is limited. There is no national plan devised for the elimination of viral hepatitis and hepatitis C has only been briefly mentioned in the National HIV Strategic Plan 2016–2021 (Nepal HIVision 2020) [5].

Multiple community- and facility-based seroepidemiological surveys for viral hepatitis and co-infections have taken place in Nepal since 1973 [6,7,8]. Studies have assessed different population groups mostly in urban areas of Kathmandu Valley and to a lesser extent in other development regions.

As new National Guidelines for Viral Hepatitis are being developed, the Joint United Nations Programme on HIV/AIDS in Nepal (UNAIDS Nepal) understands this comprehensive review is a most welcome tool for future research. We expect this document to be useful for mathematical models, advocacy for key populations, improvements in public health policy, and setting priorities for successful elimination of hepatitis B and C.

Methods

We conducted a systematic review of seroprevalence studies of hepatitis B and C following the PRISMA 2009 Flow Diagram [9]. Our main sources of data for this research were: 1) PubMed (Medline), through the following search expression “((“Hepatitis B”[Mesh] OR “Hepatitis B, Chronic”[Mesh] OR “Hepatitis B virus”[Mesh] OR “Hepatitis B Surface Antigens”[Mesh] OR “Hepatitis B Antibodies”[Mesh] OR “Hepatitis B”[Text] OR “Hepatitis C”[Mesh] OR “Hepatitis C, Chronic”[Mesh] OR “Hepatitis C Antibodies”[Mesh] OR “Hepatitis C”[Text]) AND (“Nepal”[Mesh] OR “Nepal”[Text]))”; 2) reports provided by the Government of Nepal (GoN); 3) reports authored by international agencies and non-governamental organizations (NGOs); and 4) personal correspondence to authors.

Study selection

Two researchers took part in all steps of the reviewing process. We assessed our initial search results for eligibility through title, abstract and full-text analysis. Duplicates were not identified, but two publications were found to be supplemental to previously evaluated studies. One review obtained during the search presented additional data for three studies unavailable in digital media. Personal correspondences were sent to authors to obtain additional information. We could not identify any repetition of datasets.

Publications were considered eligible for inclusion if they presented own and original data (absolute numbers or percentage) for any population group, Nepalese or residing in Nepal, at any given site and time for at least one of the following outcomes of interest: 1) hepatitis B seroprevalence, active infection or exposure; and 2) hepatitis C seroprevalence as detected by anti-HCV tests.

Selected publications were excluded if full-text material could not be retrieved, if published before 1981 and if abstract could not provide sufficient information for any of the three outcomes of interest.

Data extraction

The following data were then extracted from each eligible study included in this review: year of publication, population group, site, month and/or year of data collection, sample size, numbers/percentage of positive results for hepatitis B, C, HIV and syphilis; and authors’ name.

Seven studies did not provide details of which tests were used to define active HBV infection [7, 10,11,12,13,14,15]. One study identified did not provide details about which tests were used to define seroprevalence of exposition to HBV [16].

We chose to display results for every study total population and for as many subgroups as possible. Figures were obtained through full-text analysis and personal correspondence with authors. All numbers were thoroughly revised.

Results

This review selection process is depicted in Fig. 1, as adapted from the PRISMA 2009 Flow Diagram [9]. Initial search expression resulted in ninety different records with no duplicates. Forty-two citations were excluded after title, abstract and full-text screening and one citation was found to be supplemental. One report from Asian Network of People Who Use Drugs (ANPUD), one from HEPA Foundation/United Nations Office on Drugs and Crime (UNODC), one from United Nations Development Program (UNPD), two from Nepal Red Cross Society (NRCS) and six from Ministry of Health of Nepal (MoH), including the Global AIDS Response Progress Report 2015 (GARRP), were added to the group of forty-eight eligible citations, resulting in fifty-nine documents.

Fig. 1
figure1

Flow of article selection for the viral hepatitis B and C prevalence studies in Nepal

Five records were excluded because full-text could not be retrieved and their abstracts did not have data on any of the three outcomes of interest. Three additional documents from 1987 to 1990, which were not listed in PubMed, were identified from a review and later included in the collective. Fifty-seven documents relevant to fifty-five relevant prevalence studies were selected for this review.

Table 1 presents the collective of viral hepatitis prevalence studies with stratified population groups according to WHO key terms.

Table 1 Studies reporting hepatitis B and C in Nepal

Table 2 presents an analysis of the reviewed data and Cochran’s Q tests performed by Weill Cornell Medical College in Qatar. Estimated prevalence and heterogeneity has been presented for five population groups: PWID, populations at intermediate risk, populations at low risk (general population), populations with liver-related conditions and special clinical populations [17].

Table 2 Findings of the meta-analyses for hepatitis C virus (HCV) prevalence measures

Population groups

Candidates for blood donation account for just seven prevalence studies and yet represent approximately 90 % of the population evaluated for viral hepatitis in Nepal since 1973. This overwhelming presence of candidates for blood donation in seroprevalence studies does not contribute to the understanding of populations at increased risk of HBV, HCV and HIV co-infection in Nepal as they rarely present seroprevalence rates higher than 1 % [12, 13, 18,19,20,21,22].

It is understood that people at increased risk of HBV, HCV and HIV co-infections should be properly represented in our review. We have succeeded to identify studies for most groups of interest: general population, children, adults, pregnant women, people who inject drugs (PWID), patients attending healthcare services, sexual and household contacts of people chronically infected by HBV, sex workers (SW), healthcare workers (HCW), migrant workers, refugees/displaced persons and survivors of human trafficking.

We found only one survey of viral hepatitis in lesbian, gay, bisexual or transgender population (LGBT), including men who have sex with other men (MSM); and another in people with history of incarceration. All collected documents only referred to drug use as injection and did not acknowledge people who use drugs (PWUD) or different methods of drug administration (e.g. smoking heroin). [23, 24].

Hepatitis B

A disease preventable by vaccination, hepatitis B has been identified in our review in forty-six studies. HBsAg (surface antigen) positive tests had highest values in PWID (1.3–81.9%), [8, 25] patients with jaundice, chronic liver disease, cirrhosis or hepatocellular carcinoma (7.5–60%); [16, 26,27,28] sexual and household contacts of people chronically infected by HBV (6.6–31), [29] girls and women survivors of sex trafficking (30%), [7] Tibetan population living in Kathmandu Valley (10–20%) [30] and Nepalese people outside Nepal (2.7–19.3) [31, 32]. On the other hand, the overall prevalence of hepatitis B in Nepal is estimated at 0.9%, [33].

Children, adults and general population cohorts also present interesting ranges for figures of hepatitis B seroprevalence. Older age groups present higher values for HBsAg [20, 34] and children born after vaccine implementation display reduced disease prevalence. [35].

Unfortunately, only one document presents viral hepatitis prevalence in LGBT population (MSM included), but it lacks important information on sample size and number of positive tests.

Exposure to hepatitis B virus, defined by anti-HBc (antibody against core antigen), has been assessed only in one key population - PWID, in two studies nearly twenty years apart. In 1996, more than 80 % of PWID had positive results for anti-HBc [25] and in 2015, when less than 45 % had positive results for the same marker [8].

Hepatitis C

One of the most important causes of morbidity [36] and mortality, particularly for people living with HIV (PLWH), [37] hepatitis C seroprevalence has been featured in thirty-one studies, in a total of approximately one million people in Nepal. Prevalence rates range from zero to more than 80%, with highest figures found in PWID (85.5 in males; 24.6 in females), [38] PLHIV (43.3) and patients with hepatocellular carcinoma (17.6). [27, 38, 39].

Regardless of key population status, different prevalence rates have been observed in males and females [40]. Statistically significant differences according to gender can be verified in studies by Shrestha AC et al., between male and female candidates for blood donation in 2009 (0.69 vs. 0.33, respectively), [20] and Kinkel HT et a, between male and female PWID attending Recovering Nepal services in 2015 (19.00 vs. 60.13).

Age has been fundamental to the design of hepatitis C public health policies in many countries. It is known that age can relate to many factors in the epidemic: year of introduction of the virus, availability of tests and distribution of contaminated blood products, cumulative exposure (such as injection drug use, unprotected sexual activity across adult life), and status of harm reduction strategies [41,42,43]. In Nepal, age and hepatitis C have only been featured in two studies. De Bruyn et al. found anti-HCV to be positive in 11.8% of patients age 16–65 years attending Amp Pipal Hospital at Gorkha district in 1993; and Sawayama Y et al. found 2.27% in female villagers 45–54 years from Bhadrakali and Kotyang villages in 1996 [40, 44].

HIV co-infection prevalence

The first HIV prevalence study in Nepal dates 1989, [44] 1 year after the first case of HIV was detected in the country [45]. So far, eighteen prevalence studies also assessed at some time the HIV infection in their population, almost half a million people and roughly half of the population evaluated for HBV or HCV infection since 1985, the year of debut of anti-HIV ELISA tests.

As stated previously for overall population, candidates for blood donation represent the majority of the population tested for HIV co-infection in Nepal in the fifty-five viral hepatitis prevalence studies of this review. Yet, regardless of age and/or gender subgroups, candidates for blood donation have failed to present HIV seropositivity rates above 0.2% [20, 12, 18], constituting themselves a population of low prevalence for HIV co-infection. This data must not considered a proxy for general population, as candidates for blood donation have shown to be a “poor control group for non-genetic studies of diseases related to environmentally, behaviourally, or socially patterned exposures”, [46] but a reason to pursue further detection of viral hepatitis in priority populations.

As we evaluate the remaining studied population, we find that the highest rates of HIV infection found in this review do not belong to PWID, but sex trafficked girls and women, at an approximate 30% rate of infection in 2008 (74/246) [7). This is closely followed by PWID attending Recovering Nepal services, if accounted the participation of those with previously defined HIV status, with rates as high as 23.17% in 2015. Such findings are consonant with latest numbers of Family Health International data for HIV prevalence in PWID in Kathmandu (21% in 2009) [3] and increase of HIV and sexually transmitted infections in survivors of sex traffic, particularly for Nepalese girls and women [47,48,49].

Discussion

This review collects all available surveys performed in Nepal or with Nepalese population. It provides relevant information to policy makers, researchers and activists.

Developments of improved strategic information

It has been 44 years since the first viral hepatitis prevalence study took place in Nepal. Since then, sixty different publications, of which fifty-five are available in this review, have dedicated themselves to the better understanding of these epidemics.

Almost a quarter of these scientific publications and reports have been issued in the last 3 years. While there is still much to investigate, it is undeniable that Nepal’s civil society organizations and academia have been successful in their struggle to improve the reactive approach to viral hepatitis and HIV, shaping public health policy and visibility of key populations.

Superior strategic information and overall engagement to the epidemics lead to additional victories: the inclusion of LGBT issues in government policies, the return of harm reductions strategy in 2007, increase in donor funding for the response to HIV, and stronger ties between emerging and existing networks of key populations and representatives, healthcare professionals, academia, UNAIDS and GoN [50,51,52,53,54,55]. Such echoing common voice for change lead to the preliminary discussion of National Viral Hepatitis Guidelines and negotiation of licensed generic drugs for hepatitis C treatment at a fraction of prices offered to other developing countries [41, 56,57,58,59]. This recent collective represents a cornerstone for viral hepatitis in Nepal.

Gaps and key populations

It would seem to be that the shared modes of transmission of viral hepatitis and HIV, and the resulting similar epidemiological profiles, could translate into one equally successful public health intervention for both epidemics.

This is hardly the truth. Regardless of improvements in blood safety, availability of harm reduction services and assistance to sexually transmitted and reproductive tract infections, with significant drops in HIV prevalence since the last decade, many key populations sustain subpar decrease in hepatitis C numbers. Such is the case of PWID in Nepal: hepatitis C exceeds three times the HIV prevalence in several cohorts.

Since 2000, PWID, PLHIV, sex workers and LGBT have figured in no less than seventeen different viral hepatitis prevalence studies, almost a third of studies collected in this review, contributing without precedents to the national strategic information and deeper understanding of the response to public health interventions. Additional publications also developed initial data for other population groups such as refugees/misplaced persons and survivors of sex traffic.

Our research could not retrieve any studies regarding transgender population, male sex workers or incarcerated persons in Nepal.

Hepatitis B vaccine coverage and elimination of vertical transmission (EVT)

Hepatitis B is a highly contagious, yet preventable disease [60, 61]. In recent years, many countries have chosen to scale up maternal and newborn care in order to secure a generation ‘free of hepatitis B’.

Our review provided two studies depicting hepatitis B in infancy in Nepal. The first study states hepatitis B is responsible for approximately 5 % of the cases of acute hepatitis in children 0–15 years [14]. The second study describes observed benefits of hepatitis B vaccine introduction to children in Nepal in 2002.

While no routine for hepatitis B immunoglobulin in prevention of vertical transmission has been implemented in Nepal, the rates of acute hepatitis related to HBV infection in children are quite different than the prevalence values of HBV in pregnant women (0.32%), an indicator that perhaps household exposure during infancy, and not mother-to-child transmission, is the reason for new but likely overlooked exposure during infancy (households).

Commercial vaccines for hepatitis B have been available worldwide since 1981 [62]. In Nepal, however, it has only been introduced in 2002. After fifteen years and despite recommendations issued by GoN, the country still struggles to provide appropriate vaccine coverage [35, 63].

Official government reports state that from 2002 until 2009, third-dose hepatitis B vaccine coverage for children 12–23 months stood at approximately 80%. [63, 64] World Health Organization (WHO) and United Nations Children’s Fund (UNICEF) estimate improved coverage in 20,012 and 2013, slightly above 95%. [65] Such higher vaccine coverage numbers are not homogenous in Nepal - not all municipalities have immunization plans or appropriate structure at their disposal [63, 64]. Moreover, the intervention requires timely birth-dose vaccination for a most successful response, [66] and faces many other obstacles [67].

Hepatitis B vaccine is available to healthcare workers (HCW) in many countries. In Nepal, HCW are featured in two studies as an alternative to controls, with HBsAg seropositivity rates of 1.38 and 1.69% [26, 68]. These figures are lower than the ones presented by key populations, but still higher than those of candidates for blood donation. Further investigation reveals that HCW and students in Nepal have largely mishandled biosafety procedures while at high risk of exposure to the infective agent. Studies in tertiary care centers have shown frequent needle-stick and sharps-related injuries, and incomplete or fully ignored vaccination and post prophylaxis procedures [69,70,71].

Nevertheless, UNAIDS understands that the strengthening of the immunization plan and maternal health must be accompanied of a nationwide awareness campaign for HCW and future health professionals.

Community and the strengthening of health systems

Communities were the first responders to the HIV epidemic, nearly thirty years ago. They have continuously played an essential role in development of research, health services and shaping of public health policy worldwide, expanding their activities to sustainable and affordable vaccines and medicines for viral hepatitis.

Moreover, these collectives of advocates, researchers, clients or providers have the ability to work unisonous with marginalized populations, increasing the reach and quality of health systems and health services, often detecting overlooked issues such as stigma and discrimination. Whether leading research or promoting health services, civil society engagement improves awareness, prevention, diagnosis and retention in care. This has been the case of both viral hepatitis and HIV epidemic.

In Nepal, these initiatives are considered to be just as important as developments provided by academia, government and international agencies. It is clear that these endeavors provide a unique opportunity to fill critical gaps such as strategic information, low immunization coverage rates and elimination of mother-to-child and household transmission.

Conclusion

The present review illustrates different turning points in viral hepatitis and HIV co-infection epidemiology in Nepal. Since 1973, when the first study on viral hepatitis in the country was published, there have been many changes in the understanding of these epidemics.

These include the indirect effects of successful public health policies aimed towards HIV, such as the decrease of viral hepatitis prevalence in PWID, and their limitations, revealing overlooked population groups and issues in viral hepatitis that require public health policies of their own.

The review also allows one to witness the progressive scientific development by Nepalese researchers and institutions, and civil society representatives’ participation. Such collaboration correlates with increased number of studies and sample sizes in recent years including the survey of key populations, and will be fundamental for the success of the National HIV Strategic Plan 2016–2021 and achieving the SDG by 2030.

References

  1. 1.

    Kleinman S, Busch M. The risk of transfusion-transmitted infection: direct estimation and mathematical modelling. Ballière’s Clinical Haematology. 2000;13(4):631–49.

  2. 2.

    Government of Nepal. Ministry of Health and Population. National Centre for AIDS and STD Control. Country Progress Report Nepal. 2015.

  3. 3.

    Narain JP. Three decades of HIV/AIDS in Asia. New Delhi: Vivek Mehra for SAGE Publications India Pvt Ltd; 2012.

  4. 4.

    Government of Nepal. National Planning Comission. Sustainable development goals 2016–2030. Kathmandu: National Preliminary Report; 2015.

  5. 5.

    Government of Nepal. Ministry of Health. National Centre for AIDS and STD Control. Kathmandu: Nepal HIVision 2020 - Ending the AIDS epidemic as a public health threat, by 2030; 2016.

  6. 6.

    Hillis A, Shrestha S, Saha N. An epidemic of infectious hepatitis in the Kathmandu Valley. J Nepal Med Assoc. 1973;11(5):145–53.

  7. 7.

    Silverman JG, Decker MR, Gupta J, Dharmadhikari A, Seage G, Raj A. Syphilis and hepatitis co-infection among HIV-infected, sex-trafficked women and girls, Nepal. Emerg Infect Dis. 2008;14(6):932–4.

  8. 8.

    Kinkel HT, Karmacharya D, Shakya J, Manandhar S, Panthi S, Karmacharya P, et al. Prevalence of HIV, hepatitis B and C infections and an assessment of HCV-genotypes and two IL28B SNPs among people who inject drugs in three regions of Nepal. PLOS One. 2015;10(8):1–18.

  9. 9.

    Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.

  10. 10.

    Nuti M. The low prevalence of HBV markers in Nepal. Transact R Soc Trop Med Hyg. 1988;82:144.

  11. 11.

    Dhungel B, Dhungel K, Easow J, Singh Y. Opportunistic infection among HIV seropositive cases in Manipal Teaching Hospital, Pokhara, Nepal. Kathmandu Univ Med J. 2008;6(3):335–9.

  12. 12.

    Karki S, Ghimire P, Tiwari BR, Shrestha AC, Gautam A, Rajkarnikar M. Seroprevalence of HIV and hepatitis C co-infection among blood donors in Kathmandu Valley, Nepal. Southeast Asian J Trop Med Public Health. 2009;40(1):67–70.

  13. 13.

    Tiwari B, Ghimire P, Kandel S, Rajkarnikar M. Seroprevalence of HBV and HCV in blood donors: a study from regional blood transfusion services of Nepal. Asian J Transfus Sci. 2010;4(2):91–3.

  14. 14.

    Sudhamshu K, Sharma D, Poudyal N, Basnet BK. Acute viral hepatitis in pediatric age groups. J Nepal Med Assoc. 2014;52(193):687–91.

  15. 15.

    Barnawal SP, Niraula SR, Agrahari AK, Bista N, Jha N, Pokharel PK. Human immunodeficiency virus and hepatitis C virus coinfection in Nepal. Indian J Gastroenterol. 2014;33(2):141–5.

  16. 16.

    Shrestha SM, Shrestha S, Tsuda F, Sawada N, Tanaka T, Okamoto H, et al. Infection with GB virus C and hepatitis C virus in drug addicts, patients on maintenance hemodialysis, or with chronic liver disease in Nepal. J Med Virol. 1997;53:157–61.

  17. 17.

    Mohamoud YA, Mumtaz GR, Riome S, Miller D, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC Infectious Diseases. 2013;13:288. https://doi.org/10.1186/1471-2334-13-288.

  18. 18.

    Chander A, Pahwa V. Status of infectious disease markers among blood donors in a teaching hospital, Bhairahawa, western Nepal. J Commun Dis. 2003;35(3):188–97.

  19. 19.

    Karki S, Ghimire P, Tiwari BR, Maharjan A, Rajkarnikar M. Trends in hepatitis B and hepatitis C seroprevalence among Nepalese blood donors. Jpn J Infect Dis. 2008;61:324–6.

  20. 20.

    Shrestha AC, Ghimre P, Tiwari BR, Rajkarnikar M. Transfusion-transmissible infections among blood donors in Kathmandu, Nepal. J Infect Dev Ctries. 2009;3(10):794–7.

  21. 21.

    Nepal Red Cross Society National Blood Transfusion Service. Annual Progress Report 2069/070 (2012/13).

  22. 22.

    Nepal Red Cross Society. Annual Progress Report 2071/072 (2014/15).

  23. 23.

    Chatterjee A, Uprety L, Chapagain M, Kafle K. Drug abuse in Nepal: a rapid assessment study. Bull Narc. 1996;48(1):11–33.

  24. 24.

    Lam L. Comments on Strang et al.'s "Heroin smoking by 'chasing the dragon': origins and history". Addiction. 1997;92(6):685–95. https://0-onlinelibrary-wiley-com.brum.beds.ac.uk/doi/pdf/10.1080/09652149737665.

  25. 25.

    Shrestha S, Shrestha D, Gafney T, Maharjan K, Tsuda F, Okamoto H. Hepatitis B and C infection among drug abusers in Nepal. Trop Gastroenterol. 1996;17(4):212–3.

  26. 26.

    Shrestha SM, Tsuda F, Okamoto H, Tokita H, Horikita M, Tanaka T, et al. Hepatitis B virus subtypes and hepatitis C virus genotypes in patients with chronic liver disease in Nepal. Hepatol. 1994;19(4):805–9.

  27. 27.

    Shrestha SM, Shrestha S, Shreshta A, Tsuda F, Endo K, Takahashi M, et al. High prevalence of hepatitis B virus infection and inferior vena cava obstruction among patients with liver cirrhosis or hepatocellular carcinoma in Nepal. Hepatol. 2007;22:1921–8.

  28. 28.

    Kane MA, Bradley DW, Shrestha SM, Maynard J, Cook EH, Mishra RP, et al. Recovery of a possible etiologic agent and transmission studies in marmosets. JAMA. 1984;252(22):3140–5.

  29. 29.

    Shrestha SM, Shrestha I, Maharjan K. Family clustering of HBV infection in the household of persistent HBsAg carriers: spread of HBV by horizontal transmission. J Inst Med. 1991;13:319–26.

  30. 30.

    Shrestha SM. Seroepidemiology of viral hepatitis in Surkhet, Nepal. J Inst Med. 1987;9:1–10.

  31. 31.

    Poudel KC, Jimba M, Okumura J, Wakai S. Emerging co-infection of HIV and hepatitis B virus in far western Nepal. Trop Doct. 2006;36:186–7.

  32. 32.

    Goh K, Kong K, Heng B, Oon C. Seroepidemiology of hepatitis A and hepatitis B virus infection in a Gurkha Community in Singapore. J Med Virol. 1993;41:146–9.

  33. 33.

    Shrestha SM, Shrestha S. Chronic hepatitis B in Nepal: an Asian country with low prevalence of HBV infection. Trop Gastroenterol. 2012;33(2):95–101.

  34. 34.

    Joshi S, Ghimire G. Serological prevalence of antibodies to Human Immunodeficiency Virus (HIV) and hepatitis B virus (HBV) among healthy Nepalese males - a retrospective study. Kathmandu Univ Med J. 2003;1(4):251–5.

  35. 35.

    Upreti SR, Gurung S, Patel M, Dixit S, Krause K, Shakya G, et al. Prevalence of chronic hepatitis B virus infection before and after implementation of a hepatitis B vaccination program among children in Nepal. Vaccine. 2014;32(34):4304–9.

  36. 36.

    Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29(Suppl 1):74–81.

  37. 37.

    Sulkowski M, Thomas DL. Hepatitis in the HIV-infected person. Ann Intern Med. 2003;138(3):197–208.

  38. 38.

    Shrestha IL. Seroprevalence of antibodies to hepatitis C virus among injecting drug users from Kathmandu. Kathmandu Univ Med J. 2003;1(2):101–3.

  39. 39.

    Poudel KC, Palmer PH, Jimba M, Mizoue T, Kobayashi J, Poudel-Tandukar K. Coinfection with hepatitis C virus among HIV-positive people in Kathmandu Valley, Nepal. J Int Assoc Provid AIDS Care. 2014;13(3):277–83.

  40. 40.

    Sawayama Y, Hayashi J, Ariyama I, Furusyo N, Kawasaki T, Kawasaki M, et al. A ten year serological survey of hepatitis A, B and C viruses infections in Nepal. J Epidemiol. 1999;9(5):350–4.

  41. 41.

    Mesquita F, Santos MÉ, Benzaken A, Corrêa R, Cattapan E, Sereno L, et al. The Brazilian comprehensive response to hepatitis C: from strategic thinking to access to interferon-free therapy. BMC Public Health. 2016;16(1132)

  42. 42.

    European Centre fr Disease Prevention and Control. Hepatitis C surveillance in Europe 2013. Stockholm: ECDC; 2015.

  43. 43.

    U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. Hepatitis C - why people born from 1945–1965 should get tested. United States: CDC; 2016.

  44. 44.

    de Bruyn G, Song E. Seroepidemiology of hepatotropic viral infections in Amp Pipal, Nepal. Trop Doct. 1998;28:173–4.

  45. 45.

    Hannun J. AIDS in Nepal: communities confronting an emerging epidemic. New York: AmFAR in Association with Seven Stories Press; 1997.

  46. 46.

    Golding J, Northstone K, Miller L, Davey Smith G, Pembrey M. Differences between blood donors and a population sample: implications for case-control studies. Int J Epidemiol. 2013;42(4):1145–56.

  47. 47.

    Joffres C, Mills E, Joffres M, Khanna T, Walia H, Grund D. Sexual slavery without borders: trafficking for commercial sexual exploitation in India. Int J Equity Health. 2008;7(22)

  48. 48.

    Sarkar K, Bal B, Mukherjee R, Chakraborty S, Saha S, Ghosh A, et al. Sex-trafficking, violence, negotiating skill, and HIV infection in brother-based sex workers of Eastern India, adjoining Nepal, Bhutan, and Bangladesh. J Health Popul Nutr. 2008;26(2):223–31.

  49. 49.

    Silverman J, Decker M, Gupta J, Maheshwari A, Willis B, Raj A. HIV prevalence and predictors of infection in sex-trafficked Nepalese girls and women. JAMA. 2007;298(5):536–42.

  50. 50.

    UNDP, USAID. Being LGBT in Asia. Bangkok: Nepal Country Report; 2014.

  51. 51.

    Federal Ministry for Economic Cooperation and Development. Division for Health and Population. Opioid substitution therapy in Nepal. Bonn: Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) GmbH; 2016.

  52. 52.

    UNDP, Williams Institute. Surveying Nepal’s sexual and gender minorities: an inclusive approach. Bangkok: UNDP; 2014.

  53. 53.

    UNDP. Lost in transition: transgender people, rights and HIV vulnerability in the Asia-Pacific Region. Bangkok: UNDP; 2012.

  54. 54.

    Ministry of Health and Population. National Centre for AIDS and STI Control. National targeted intervention operational guidelines - injecting drug users. 2010.

  55. 55.

    Thomson N. Harm reduction history, response, and current trends in Asia. J Food Drug Anal. 2013;21(Suppl 4):113–6.

  56. 56.

    Natco Pharma. News & Announcements. 2017. http://natcopharma.co.in/about/news/. Accessed 21 Feb 2017.

  57. 57.

    Gilead Sciences, Inc. Chronic hepatitis C treatment expansion - generic manufacturing for developing countries. 2015.

  58. 58.

    Bristol-Myers Squibb Company, Medicines Patent Pool. Medicines Patent Pool. 2015. https://medicinespatentpool.org/uploads/2015/11/MPP-HCV-License-Agreement-BMS-FINAL-Web-00000002.pdf. Accessed 21 Feb 2017.

  59. 59.

    Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, et al. Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis. PLOS Med. 2016;13(5):e1002032.

  60. 60.

    Lavanchy D. Chronic viral hepatitis as a public health issue in the world. Best Pract Res Clin Gastroenterol. 2008;22(6):991–1008.

  61. 61.

    Mandell G, Bennett J, Mandell DR. In: Mandell JEBRD GL, editor. Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 7th ed. Philadelphia: Elsevier; 2010.

  62. 62.

    Blumberg BS. The discovery of the hepatitis B virus and the invention of the vaccine: a scientific memoir. J Gastroenterol Hepatol. 2002;17(Suppl):502–3.

  63. 63.

    Ministry of Health & Population. Department of Health Services. Child Health Division. National immunization program - reaching every child - comprehensive multi-year plan 2068/2072 (2011–2016). Kathmandu: Government of Nepal; 2011.

  64. 64.

    Ministry of Health. Department of Health Services. Child Health Division. National immunization program of Nepal - reaching every village - multi-year plan of action 2007–2011. Kathmandu: Government of Nepal; 2007.

  65. 65.

    Berger S. Hepatitis B: global status: GIDEON Informatics Inc; 2016.

  66. 66.

    World Health Organization. Global health sector strategy on viral hepatitis, 2016–2021. Geneva: World Health Organization; 2016.

  67. 67.

    Tajiri K, Shimizu Y. Unsolved problems and future perspectives of hepatitis B virus vaccination. World J Gastroenterol. 2015;21(23):7074–83.

  68. 68.

    Shrestha S, Bhattarai M. Study of hepatitis B among different categories of health care workers. J Coll Physicians Surg Pak. 2006;16(2):108–11.

  69. 69.

    Bhattarai S, Smriti K, Pradhan PM, Lama S, Rijal S. Hepatitis B vaccination status and needle-stick and sharps-related injuries among medical school students in Nepal: a cross-sectional study. BMC Res Notes. 2014;7(774)

  70. 70.

    Gurubacharya D, Mathura K, Karki D. Knowledge, attitude and practices among health care workers on needle-stick injuries. Kathmandu Univ Med J. 2003;1(2):91–4.

  71. 71.

    Singh B, Paudel B, KC S. Knowledge and practice of health care workers regarding needle stick injuries in a tertiary care center of Nepal. Kathmandu Univ Med J. 2015;13:230–3.

  72. 72.

    Shrestha SM. Acute sporadic viral hepatitis in Nepal. Trop Gastroenterol. 1987;8:99–105.

  73. 73.

    Reynolds RD, Moser P, Acharya S, McConnell W, Andon M, Howard MP. Nutritional and medical status of lactating women and their infants in the Kathmandu valley of Nepal. Am J Clin Nutr. 1988;47:722–8.

  74. 74.

    Mertens T, Tondorf G, Siebolds M, Kruppenbacher J, Shrestha S, Mauff G, et al. Epidemiology of HIV and hepatitis B virus (HBV) in selected African and Asian populations. Infection. 1989;17(1):4–7.

  75. 75.

    Shrestha SM. Seroepidemiology of hepatitis B in Nepal. J Commun Dis. 1990;22:27–32.

  76. 76.

    Bhatta P, Thapa S, Neupane S, Baker J, Friedman M. Commercial sex workers in Kathmandu Valley: profile and prevalence of sexually transmitted diseases. J Nepal Med Assoc. 1994;32(111):191–203.

  77. 77.

    Rai SK, Shibata H, Satoh M, Murakoso K, Sumi K, Kubo T, et al. Seroprevalence of hepatitis B and C viruses in Eastern Nepal. Kansenshogaku Zasshi. 1994;68(12):1492–7.

  78. 78.

    Nakashima K, Kashiwagi S, Noguchi A, Hirata M, Hayashi J, Kawasaki T, et al. Human T-lymphotropic virus type-I, and hepatitis A, B and C viruses in Nepal: a serological survey. J Trop Med Hyg. 1995;98(5):347–50.

  79. 79.

    Manandhar K, Shrestha B. Prevalence of HBV infection among the healthy Nepalese males: a serological survey. J Epidemiol. 2000;10(6):410–3.

  80. 80.

    Manandhar K, Shrestha B. Prevalence of hepatitis B virus infection amongst healthy Nepalese males. Trop Gastroenterol. 1998;19(4):145–7.

  81. 81.

    Bidya S. HBsAg carriers among healthy Nepalese men: a serological survey. J Health Popul Nutr. 2002;20(3):235–8. http://www.recoveringnepal.org.np/image/info_materials/20111103081156838553767.pdf.

  82. 82.

    Chiba H, Takezaki T, Neupani D, Kim J, Yoshida S, Mizoguchi E, et al. An epidemiological study of HBV, HCV and HTLV-1 in Sherpas of Nepal. Asian Pac J Cancer Prev. 2004;5:370–3.

  83. 83.

    Shah B, Bhattacharya S, Parija S. Seroprevalence of hepatitis B virus among Bhutanese refugees residing in Nepal. Kathmandu Univ Med J. 2005;3(3):239–42.

  84. 84.

    Shrestha P, Bhandari D, Sharma D, Bhandari B. A study of viral hepatitis during pregnancy in Nepal Medical College Teaching Hospital. Nepal Med Coll J. 2009;11(3):192–4.

  85. 85.

    HEPA Foundation, United Nations Office on Drugs and Crime (UNODC). Prevalence of hepatitis C in OST client.

  86. 86.

    Asian Network of People Who Use Drugs. Barriers to hepatitis C diagnosis, management and treatment among people who inject drugs in 4 Asian countries: a community led study in India, Indonesia, Malaysia & Nepal. Bangkok: Asian Network of People who Use Drugs (ANPUD); 2011.

  87. 87.

    Adhikari P, Pathak U, Uprety D, Sapkota S. Profile of ascites patients admitted in Nepal Medical College Teaching Hospital. Nepal Med Coll J. 2012;14(2):111–3.

  88. 88.

    Ojha CR, Khagendra K, Shakya G. Co-infection of hepatitis C among HIV-infected population with different risk groups in Kathmandu, Nepal. Biomed Res. 2013;24(4):441–4.

  89. 89.

    Supram HS, Gokhale S, Sathian B, Bhatta DR. Hepatitis B virus (HBV) and hepatitis C virus (HCV) co-infection among HIV infected individuals at tertiary care hospital in Western Nepal. Nepal J Epidemiol. 2015;5(2):488–93.

  90. 90.

    Ministry of Health and Population. National Centre for AIDS and STD Control. Integrated biological and behavioral surveillance (IBBS) survey among people who inject drugs (PWID-male) in the Eastern Terai Highway Districts (Jhapa, Morang and Sunsari) of Nepal, 2015. Teku, Kathmandu: Government of Nepal; 2015.

  91. 91.

    Ministry of Health and Population. National Centre for AIDS and STD Control. Integrated biological and behavioral surveillance (IBBS) survey among people who inject drugs (PWID) in Kathmandu Valley, 2015. Teku, Kathmandu: Government of Nepal; 2015.

  92. 92.

    Ministry of Health and Population. National Centre for AIDS and STD Control. Integrated biological and behavioral surveillance (IBBS) survey among people who inject drugs (PWIDs) in Pokhara Valley, 2015. Kathmandu: Government of Nepal; 2015.

  93. 93.

    United Nations Development Program/Department for International Development/Center for Molecular Dynamics Nepal. Draft report of four PLHIV surveys. 2012.

  94. 94.

    Loewinger G, Sharma B, Karki DK, Khatiwoda P, Kainee S, Poudel K. Low knowledge and perceived hepatitis C risk despite high risk behaviour among injection drug users in Kathmandu, Nepal. Int J Drug Policy. 2016;33:75–82.

  95. 95.

    Ministry of Health. National Centre for AIDS and STD Control. Integrated biological and behavioral surveillance (IBBS) survey among female injecting drug users in Kathmandu Valley. Teku, Kathmandu: Government of Nepal; 2016.

  96. 96.

    Ministry of Health. National Centre for AIDS and STD Control. Integrated biological and behavioral surveillance (IBBS) survey among people who inject drugs (PWID-male) in Western to Far Western Terai Highway Districts of Nepal. Kathmandu: Government of Nepal; 2016.

  97. 97.

    Nepal A, Kunwar B. Evidence of hepatitis C virus infection and associated treatment in Nepal. J Mol Biomark Diagn. 2016;7(2):270.

Download references

Acknowledgements

We are grateful for the support provided by the Biostatistics, Epidemiology, and Biomathematics Research Core at the Weill Cornell Medical College in Qatar. The authors are also grateful for the valuable suggestions and comments by the reviewers of this article.

Availability of data and materials

All data present in this review is accessible through scientific journals and reports.

Author information

MCMN and KB performed the systematic review. KB supervised the research and provided inputs for discussion. All authors contributed equally to the discussion, conclusion and review of this manuscript. All authors read and approved the final manuscript.

Correspondence to Marcelo Contardo Moscoso Naveira or Komal Badal.

Ethics declarations

Ethics approval and consent to participate

This study does not require ethics committee approval or written informed consent as it relies entirely on published available data.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Naveira, M.C.M., Badal, K., Dhakal, J. et al. Seroprevalence of hepatitis B and C in Nepal: a systematic review (1973–2017). Hepatology Medicine Policy 3, 10 (2018) doi:10.1186/s41124-018-0039-2

Download citation

Keywords

  • Viral hepatitis
  • Hepatitis B
  • Hepatitis C
  • Systematic review
  • Epidemiology
  • Nepal